An FDA advisory panel recommended broader use of some compounded peptides while narrowly stopping others, moving the policy conversation closer to the U.S. government’s push for greater access to certain unapproved compounds. The panel supported manufacturing of epitalon but voted against manufacturing emideltide. The votes followed an earlier day in which the same panel recommended allowing pharmacies to make four other peptides, while keeping restrictions around the evidence base. The developments were framed around recommendations tied to Robert F. Kennedy Jr.’s broader “MAHA” agenda. Biotech stakeholders should note the signals around how regulators and advisory bodies evaluate limited clinical evidence for peptide compounds, and how quickly a compounding pathway could expand supply for non-approved therapies.